ДОЛТОН Джеймс Т. (US),ДОДСОН Шонтель (US),СТЕЙНЕР Митчелл С. (US)
申请号：
RU2013149821/15
公开号：
RU2013149821A
申请日:
2012.04.09
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating, reducing severity, reducing morbidity, delaying the onset or attenuation of the pathogenesis of muscle atrophy in a human subject with non-small cell lung cancer, comprising the step of administering to said subject a compound - selective androgen receptor modulator (SARM) of formula II: where X is O； Z is a hydrogen bond acceptor, NO, CN, COR, CONHR； Y is a fat-soluble group, CF, CH, formyl, alkoxy, H, F, I, Br, Cl, Sn (R)； R is alkyl, aryl, phenyl, alkenyl , haloalkyl, haloalkenyl, halogen or OH； and Q is alkyl, halogen, N (R), CN, NHCOCH, NHCOCF, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH, NHCSCF, NHCSR, NHSOCH, NHSOR, OR, COR, OCOR, OSOR, SOR or SR, acetamido-, trifluoroacetamido-, alkylamine, ether group, alkyl, N-sulfonyl, O-sulfonyl, alkylsulfonyl, carbonyl or ketone. 2. The method according to claim 1, characterized in that said compound is characterized by the structure of formula III: 3. The method of claim 1, wherein said administration comprises administering a pharmaceutical composition comprising said compound and / or isomer thereof, a pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof； and a pharmaceutically acceptable carrier. 4. The method according to claim 1, characterized in that said method further increases the functional status of said subject with non-small cell lung cancer. The method according to claim 4, characterized in that said method further improves the quality of life of said subject with non-small cell lung cancer. The method according to claim 1, characterized in that the method increases the survival of the specified subject. The method of treatment, reducing severity, reducing zab�1. Способ лечения, снижения степени тяжести, снижения заболеваемости, задержки начала или ослабления патогенеза атрофии мышц у субъекта-человека с немелкоклеточным раком легких, включающий этап введения указанному субъекту соединения - селективного модулятора рецепторов анд
